{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:33:35Z","timestamp":1790645615242,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:00:00Z","timestamp":1555459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Despite extensive progress in understanding the pathology of Alzheimer\u2019s disease (AD) over the last 50 years, clinical trials based on the amyloid\u2013beta (A\u03b2) hypothesis have kept failing in late stage human trials. As a result, just four old drugs of limited clinical outcomes and numerous side effects are currently used for AD therapy. This article assesses the common pharmacological targets and therapeutic principles for current and future drugs. It also underlines the merits of natural products acting through a polytherapeutic approach over a monotherapy option of AD therapy. Multi-targeting approaches through general antioxidant and anti-inflammatory mechanisms coupled with specific receptor and\/or enzyme-mediated effects in neuroprotection, neuroregeneration, and other rational perspectives of novel drug discovery are emphasized.<\/jats:p>","DOI":"10.3390\/molecules24081519","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T11:56:45Z","timestamp":1555502205000},"page":"1519","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Natural Products in Alzheimer\u2019s Disease Therapy: Would Old Therapeutic Approaches Fix the Broken Promise of Modern Medicines?"],"prefix":"10.3390","volume":"24","author":[{"given":"Solomon","family":"Habtemariam","sequence":"first","affiliation":[{"name":"Pharmacognosy Research Laboratories &amp; Herbal Analysis Services UK, University of Greenwich, Central Avenue, Chatham-Maritime, Kent ME4 4TB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine Study Group. Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","article-title":"Lack of evidence for the efficacy of memantine in mild Alzheimer disease","volume":"68","author":"Schneider","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_3","unstructured":"ADA (Alzheimers Disease Association) (2019, March 28). Medications for Memory. Available online: https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/medications-for-memory."},{"key":"ref_4","unstructured":"AS (Alzheimer\u2019s Societry UK) (2019, March 28). Drug treatments for Alzheimer\u2019s disease. Available online: https:\/\/www.alzheimers.org.uk\/about-dementia\/treatments\/drugs\/drug-treatments-alzheimers-disease."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"pii","DOI":"10.1101\/cshperspect.a024539","article-title":"Genetics of \u03b2-Amyloid precursor protein in Alzheimer\u2019s disease","volume":"7","author":"Tcw","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mad.2016.04.005","article-title":"Genome instability in Alzheimer disease","volume":"161","author":"Hou","year":"2017","journal-title":"Mech. Ageing Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","article-title":"Levels of soluble apolipoprotein E\/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples","volume":"288","author":"Tai","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_8","unstructured":"WHO (2019, March 28). Dementia. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref_9","unstructured":"ADI (Alzheimeris Disease international) (2019, March 28). Dementia Statistics. Available online: https:\/\/www.alz.co.uk\/research\/statistics."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"a006171","DOI":"10.1101\/cshperspect.a006171","article-title":"The neuropsychological profile of Alzheimer disease","volume":"2","author":"Weintraub","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_11","first-page":"a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Frosch","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(18)31425-9","article-title":"Alzheimer\u2019s disease research: The future of BACE inhibitors","volume":"391","author":"Burki","year":"2018","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1523\/JNEUROSCI.5980-08.2009","article-title":"A role for synaptic zinc in activity-dependent A\u03b2 oligomer formation and accumulation at excitatory synapses","volume":"29","author":"Deshpande","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.neuroscience.2010.07.044","article-title":"Effect of transition metals in synaptic damage induced by amyloid beta peptide","volume":"170","author":"Uranga","year":"2010","journal-title":"Neuroscience"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1073\/pnas.0809057106","article-title":"Increasing Cu bioavailability inhibits A\u03b2 oligomers and tau phosphorylation","volume":"106","author":"Crouch","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.04.003","article-title":"Biological metals and Alzheimer\u2019s disease: Implications for therapeutics and diagnostics","volume":"92","author":"Duce","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neuroimage.2010.11.073","article-title":"Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer\u2019s disease","volume":"55","author":"Leskovjan","year":"2011","journal-title":"NeuroImage"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1074\/jbc.M110.158980","article-title":"Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation","volume":"286","author":"Liu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer\u2019s disease","volume":"14","author":"Hull","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending-dose studies of Vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"ref_21","first-page":"75","article-title":"Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in individuals with early Alzheimer\u2019s disease: Amyloid imaging positron emission tomography and safety results from a phase 2 study","volume":"3","author":"Sadowsky","year":"2016","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nlm.2003.07.003","article-title":"Acetylcholine modulation of neural systems involved in learning and memory","volume":"80","author":"Gold","year":"2003","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer\u2019s disease: A disorder of cortical cholinergic innervations","volume":"219","author":"Coyle","year":"1983","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1023\/A:1022869222652","article-title":"Cholinesterases: New roles in brain function and in Alzheimer\u2019s disease","volume":"28","author":"Giacobini","year":"2003","journal-title":"Neurochem. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.neubiorev.2010.04.001","article-title":"The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies","volume":"34","author":"Klinkenberg","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.31887\/DCNS.2000.2.3\/cgilles","article-title":"Pharmacological models in Alzheimer\u2019s disease research","volume":"2","author":"Gilles","year":"2000","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1742-7843.2011.00677.x","article-title":"Tacrine treatment at high dose suppresses the recognition memory in juvenile and adult mice with attention to hepatotoxicity","volume":"108","author":"Pan","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_31","first-page":"160","article-title":"Hepatotoxicity of tacrine: Occurrence of membrane fluidity alterations without involvement of lipid peroxidation","volume":"294","author":"Galisteo","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00002093-199806000-00007","article-title":"Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience","volume":"12","author":"Gracon","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mad.2005.09.016","article-title":"Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer\u2019s disease","volume":"127","author":"Lanari","year":"2006","journal-title":"Mech. Ageing Dev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.2174\/1381612821666150914121149","article-title":"Treatment Options in Alzheimer\u00b4s Disease: The GABA Story","volume":"21","author":"Solas","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1515\/tnsci-2016-0007","article-title":"The serotonergic system and cognitive function","volume":"7","author":"Pivac","year":"2016","journal-title":"Transl. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pneurobio.2016.04.001","article-title":"Monoaminergic neuropathology in Alzheimer\u2019s disease","volume":"151","author":"Wray","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcell.2014.00045","article-title":"Cellular prion protein and NMDA receptor modulation: Protecting against excitotoxicity","volume":"2","author":"Black","year":"2014","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00424-010-0809-1","article-title":"Glutamate receptors, neurotoxicity and neurodegeneration","volume":"460","author":"Lau","year":"2010","journal-title":"Pflug. Arch."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","article-title":"Extrasynaptic NMDA receptor involvement in central nervous system disorders","volume":"82","author":"Parsons","year":"2014","journal-title":"Neuron"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fnmol.2011.00024","article-title":"Modulation of GSK-3 as a therapeutic strategy on tau pathologies","volume":"4","author":"Medina","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3233\/JAD-170176","article-title":"Protein phosphorylation is a key mechanism in Alzheimer\u2019s disease","volume":"58","author":"Oliveira","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer\u2019s 1907 paper, \u2018Uber eine eigenartige Erkankung der Hirnrinde\u2019","volume":"8","author":"Alzheimer","year":"1995","journal-title":"Clin. Anat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-180740","article-title":"The role of apolipoprotein E isoforms in Alzheimer\u2019s disease","volume":"68","author":"Roda","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41598-018-19699-y","article-title":"Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer\u2019s disease mouse model 5xFAD","volume":"8","author":"Yang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(18)30490-3","article-title":"The role of astroglia in Alzheimer\u2019s disease: Pathophysiology and clinical implications","volume":"18","author":"Arranz","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/glia.22298","article-title":"Comparison of polarization properties of human adult microglia and blood-derived macrophages","volume":"60","author":"Durafourt","year":"2012","journal-title":"Glia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.imbio.2016.06.007","article-title":"Modeling complement-driven diseases in transgenic mice: Values and limitations","volume":"221","author":"Ueda","year":"2016","journal-title":"Immunobiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jmb.2019.01.045","article-title":"Microglia in Alzheimer\u2019s disease: Exploring how genetics and phenotype influence risk","volume":"431","author":"McQuade","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/glia.20468","article-title":"Microglia derived from aging mice exhibit an altered inflammatory profile","volume":"55","author":"Sierra","year":"2007","journal-title":"Glia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tins.2006.07.001","article-title":"Microglial senescence: Does the brain\u2019s immune system have an expiration date?","volume":"29","author":"Streit","year":"2006","journal-title":"Trends Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-2094-2-9","article-title":"Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer\u2019s disease","volume":"2","author":"Patel","year":"2005","journal-title":"J. Neuroinflamm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1523\/JNEUROSCI.23-07-02665.2003","article-title":"A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation","volume":"23","author":"Bamberger","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","article-title":"Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\u2019s disease mice","volume":"28","author":"Hickman","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1471-4914(01)02173-6","article-title":"Evidence of oxidative damage in Alzheimer\u2019s disease brain: Central role for amyloid beta-peptide","volume":"7","author":"Butterfield","year":"2001","journal-title":"Trends Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbadis.2009.10.006","article-title":"Mitochondrial dysfunction is a trigger of Alzheimer\u2019s disease pathophysiology","volume":"1802","author":"Moreira","year":"2010","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9024","DOI":"10.1021\/ic201233b","article-title":"Iron(II) binding to amyloid-\u03b2, the Alzheimer\u2019s peptide","volume":"50","author":"Bijani","year":"2011","journal-title":"Inorg. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","article-title":"Iron accumulation in Alzheimer disease is a source of redox-generated free radicals","volume":"94","author":"Smith","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/anie.201508597","article-title":"Free superoxide is an intermediate in the production of H2O2 by copper(I)-A\u03b2 peptide and O2","volume":"55","author":"Reybier","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10534-017-0005-2","article-title":"Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron","volume":"30","author":"Tahmasebinia","year":"2017","journal-title":"Biometals"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.ccr.2012.03.012","article-title":"Affinity of copper and zinc ions to proteins and peptides related to neurodegenerative conditions (A\u03b2, APP, \u03b1-synuclein, PrP)","volume":"256","author":"Zawisza","year":"2012","journal-title":"Coord. Chem. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ccr.2011.07.004","article-title":"Structural characterization of Cu2+, Ni2+ and Zn2+ binding sites of model peptides associated with neurodegenerative diseases","volume":"256","author":"Migliorini","year":"2012","journal-title":"Coord. Chem. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1039\/c4mt00016a","article-title":"Use of a new water-soluble Zn sensor to determine Zn affinity for the amyloid-\u03b2 peptide and relevant mutants","volume":"6","author":"Noel","year":"2014","journal-title":"Metallomics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.redox.2018.01.008","article-title":"13 reasons why the brain is susceptible to oxidative stress","volume":"15","author":"Cobley","year":"2018","journal-title":"Redox Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"44557","DOI":"10.1074\/jbc.M111.279208","article-title":"SOD1 (copper\/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease","volume":"286","author":"Murakami","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/10715760701861373","article-title":"Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer\u2019s disease from mild cognitive impairment","volume":"42","author":"Bermejo","year":"2008","journal-title":"Free Radic. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1196\/annals.1297.059","article-title":"Glutathione metabolism during aging and in Alzheimer disease","volume":"1019","author":"Liu","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1471-4159.2011.07500.x","article-title":"The role of metallobiology and amyloid-beta peptides in Alzheimer\u2019s disease","volume":"120","author":"Roberts","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0891-5849(00)00494-9","article-title":"Redox-active iron mediates amyloid-beta toxicity","volume":"30","author":"Rottkamp","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1006\/bbrc.1995.2678","article-title":"The role of iron in beta amyloid toxicity","volume":"216","author":"Schubert","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1002\/cpph.57","article-title":"Preclinical models of Alzheimer\u2019s disease: Relevance and translational validity","volume":"84","author":"Mullane","year":"2019","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00702-017-1729-4","article-title":"Innate immunity in Alzheimer\u2019s disease: The relevance of animal models?","volume":"125","author":"Nicoll","year":"2018","journal-title":"J. Neural. Transm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41583-018-0054-8","article-title":"Rodent models for Alzheimer disease","volume":"19","author":"Bodea","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_75","first-page":"63","article-title":"Therapeutic potentials of herbal drugs for Alzheimer\u2019s disease\u2014An overview","volume":"55","author":"Kumar","year":"2017","journal-title":"Indian J. Exp. Biol."},{"key":"ref_76","first-page":"3574012","article-title":"Plants-derived neuroprotective agents: Cutting the cycle of cell death through multiple mechanisms","volume":"2017","author":"Elufioye","year":"2017","journal-title":"eCAM"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/1389557516666161130100947","article-title":"Protective effects of caffeic acid and the Alzheimer\u2019s brain: An update","volume":"17","author":"Habtemariam","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_78","first-page":"387","article-title":"Neuroprotective effects of citrus fruit-derived flavonoids, nobiletin and tangeretin in Alzheimer\u2019s and Parkinson\u2019s disease","volume":"16","author":"Braidy","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2174\/0929867323666160217124333","article-title":"Rutin as a natural therapy for Alzheimer\u2019s disease: Insights into its mechanisms of action","volume":"23","author":"Habtemariam","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.phrs.2017.10.008","article-title":"Apigenin as neuroprotective agent: Of mice and men","volume":"128","author":"Nabavi","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2174\/1568026616666160204121725","article-title":"Neuroprotective effects of fisetin in Alzheimer\u2019s and Parkinson\u2019s Diseases: From chemistry to medicine","volume":"16","author":"Nabavi","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neuint.2015.09.006","article-title":"Neuroprotective effects of chrysin: From chemistry to medicine","volume":"90","author":"Nabavi","year":"2015","journal-title":"Neurochem. Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.phytol.2016.10.005","article-title":"Synthesis and evaluation of berberine derivatives and analogues as potential anti-acetylcholinesterase and antioxidant agents","volume":"18","author":"Roselli","year":"2016","journal-title":"Phytochem. Lett."},{"key":"ref_84","first-page":"1089","article-title":"The therapeutic potential of Berberis darwinii stem-bark: Quantification of berberine and in vitro evidence for Alzheimer\u2019s disease therapy","volume":"6","author":"Habtemariam","year":"2011","journal-title":"Nat. Prod. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Habtemariam, S. (2018). Iridoids and other monoterpenes in the Alzheimer\u2019s brain: Recent development and future prospects. Molecules, 23.","DOI":"10.3390\/molecules23010117"},{"key":"ref_86","first-page":"2680409","article-title":"The therapeutic potential of rosemary (Rosmarinus officinalis) diterpenes for Alzheimer\u2019s disease","volume":"2016","author":"Habtemariam","year":"2016","journal-title":"eCAM"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(02)00915-1","article-title":"Chrysamine G and its derivative reduce amyloid \u03b2-induced neurotoxicity in mice","volume":"333","author":"Ishii","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13905","DOI":"10.1074\/jbc.M211976200","article-title":"Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer\u2019s disease","volume":"278","author":"Adessi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1399-3011.2002.11002.x","article-title":"Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits A\u03b21-40 fibrillogenesis","volume":"60","author":"Gordon","year":"2002","journal-title":"J. Pept. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.271.15.8545","article-title":"Arrest of \u03b2-amyloid fibril formation by a pentapeptide ligand","volume":"271","author":"Tjernberg","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"12601","DOI":"10.1074\/jbc.272.19.12601","article-title":"Controlling amyloid \u03b2-peptide fibril formation with protease-stable ligands","volume":"272","author":"Tjernberg","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nm0798-822","article-title":"\u03b2-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer\u2019s therapy","volume":"4","author":"Soto","year":"1998","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jnr.20025","article-title":"Curcumin has potent anti-amiloidogenic effects for Alzheimer\u2019s \u03b2-amyloid fibrils in vitro","volume":"75","author":"Ono","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbadis.2004.06.008","article-title":"Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer\u2019s \u03b2-amyloid fibrils in vitro","volume":"1690","author":"Ono","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1471-4159.2002.00904.x","article-title":"Nordihydroguaigaretic acid potently breaks down pre-formed Alzheimer\u2019s \u03b2-amyloid fibrils in vitro","volume":"81","author":"Ono","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.bmc.2016.12.037","article-title":"Synthesis, anticholinesterase activity and molecular modelling study of novel carbamate-substituted thymol\/carvacrol derivatives","volume":"25","author":"Kurt","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cbdd.12991","article-title":"Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase","volume":"90","author":"Stavrakov","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jgr.2015.02.002","article-title":"Ginsenoside Rd and ischemic stroke; a short review of literatures","volume":"39","author":"Nabavi","year":"2015","journal-title":"J. Ginseng Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.2174\/1568026615666150610142647","article-title":"Neuroprotective effects of ginkgolide B against ischemic stroke: A review of current literature","volume":"15","author":"Nabavi","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-018-08523-5","article-title":"Therapeutic approaches to Alzheimer\u2019s disease through modulation of NRF2","volume":"21","author":"Bahn","year":"2019","journal-title":"Neuromol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Schmidlin, C.J., Dodson, M.B., Madhavan, L., and Zhang, D.D. (2019). Redox regulation by NRF2 in aging and disease. Free Radic. Biol. Med.","DOI":"10.1016\/j.freeradbiomed.2019.01.016"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cbi.2019.01.010","article-title":"Curcumin analogues attenuate A\u03b225-35-induced oxidative stress in PC12 cells via Keap1\/Nrf2\/HO-1 signaling pathways","volume":"305","author":"Xu","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"605","DOI":"10.14336\/AD.2017.0903","article-title":"Neuroprotective effect of caffeic acid phenethyl ester in a mouse model of Alzheimer\u2019s disease involves Nrf2\/HO-1 pathway","volume":"9","author":"Morroni","year":"2018","journal-title":"Aging Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ptr.6107","article-title":"Berberine: Pathways to protect neurons","volume":"32","author":"Lin","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11064-017-2421-7","article-title":"Resveratrol Attenuates the Cytotoxicity Induced by Amyloid-\u03b21-42 in PC12 Cells by Upregulating Heme Oxygenase-1 via the PI3K\/Akt\/Nrf2 Pathway","volume":"43","author":"Hui","year":"2018","journal-title":"Neurochem. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12031-018-1210-3","article-title":"Ginsenoside compound K regulates amyloid \u03b2 via the Nrf2\/Keap1 signaling pathway in mice with scopolamine hydrobromide-induced memory impairments","volume":"67","author":"Yang","year":"2019","journal-title":"J. Mol. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lfs.2019.03.055","article-title":"Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer\u2019s disease","volume":"224","author":"Zaplatic","year":"2019","journal-title":"Life Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.1021\/acs.jafc.7b03252","article-title":"Resveratrol Ameliorates Tau Hyperphosphorylation at Ser396 Site and Oxidative Damage in Rat Hippocampal Slices Exposed to Vanadate: Implication of ERK1\/2 and GSK-3\u03b2 Signaling Cascades","volume":"65","author":"Jhang","year":"2017","journal-title":"J. Agric. Food. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1142\/S0192415X17500902","article-title":"Curcumin decreases hyperphosphorylation of tau by down-regulating caveolin-1\/GSK-3\u03b2 in N2a\/APP695swe cells and APP\/PS1 double transgenic Alzheimer\u2019s disease mice","volume":"45","author":"Sun","year":"2017","journal-title":"Am. J. Chin. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2017.09.114","article-title":"Hyperforin attenuates aluminum-induced A\u03b2 production and tau phosphorylation via regulating Akt\/GSK-3\u03b2 signaling pathway in PC12 cells","volume":"96","author":"Huang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Xu, W., Liu, J., Ma, D., Yuan, G., Lu, Y., and Yang, Y. (2017). Capsaicin reduces Alzheimer-associated tau changes in the hippocampus of type 2 diabetes rats. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172477"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4103\/1673-5374.233438","article-title":"The brain-derived neurotrophic factor in neuronal plasticity and neuroregeneration: New pharmacological concepts for old and new drugs","volume":"13","author":"Habtemariam","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1073\/pnas.0913572107","article-title":"A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone","volume":"107","author":"Jang","year":"2010","journal-title":"PNAS"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/1673-5374.198964","article-title":"Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury","volume":"12","author":"Wurzelmann","year":"2017","journal-title":"Neural Regen Res."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Stonesifer, C., Corey, S., Ghanekar, S., Diamandis, Z., Acosta, S.A., and Borlongan, C.V. (2017). Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms. Prog. Neurobiol., 94\u2013131.","DOI":"10.1016\/j.pneurobio.2017.07.004"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e1800707","DOI":"10.1002\/mnfr.201800707","article-title":"Cerebrosides from Sea Cucumber Improved A\u03b21-42-Induced Cognitive Deficiency in a Rat Model of Alzheimer\u2019s Disease","volume":"63","author":"Li","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Zhu, Y.Z., Liu, J.W., Wang, X., Jeong, I.H., Ahn, Y.J., and Zhang, C.J. (2018). Anti-BACE1 and antimicrobial activities of steroidal compounds isolated from marine Urechis unicinctus. Mar. Drugs, 16.","DOI":"10.3390\/md16030094"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1179\/1743132814Y.0000000422","article-title":"Assessment of anti-amyloidogenic activity of marine red alga G. acerosa against Alzheimer\u2019s beta-amyloid peptide 25\u201335","volume":"37","author":"Syad","year":"2015","journal-title":"Neurol. Res."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Moodie, L.W.K., Sep\u010di\u0107, K., Turk, T., Frange, \u017d.R., and Svenson, J. (2019). Natural cholinesterase inhibitors from marine organisms. Nat. Prod. Rep.","DOI":"10.1039\/C9NP00010K"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jafc.8b00988","article-title":"Effects of astaxanthin and docosahexaenoic-acid-acylated astaxanthin on Alzheimer\u2019s disease in APP\/PS1 double-transgenic mice","volume":"66","author":"Che","year":"2018","journal-title":"J. Agric. Food Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e01037","DOI":"10.1002\/brb3.1037","article-title":"Protective effects of omega-3 fatty acids against Alzheimer\u2019s disease in rat brain endothelial cells","volume":"8","author":"Wang","year":"2018","journal-title":"Brain Behav."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mam.2018.09.003","article-title":"Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection","volume":"64","author":"Bazan","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1574884713666180807145648","article-title":"A recent update on the effects of omega-3 fatty acids in Alzheimer\u2019s disease","volume":"13","author":"Ajith","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3233\/JAD-180160","article-title":"Nutritional intervention to prevent Alzheimer\u2019s disease: Potential benefits of xanthophyll carotenoids and omega-3 fatty acids combined","volume":"64","author":"Nolan","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.nbd.2018.11.026","article-title":"Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and \u03b1-lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer\u2019s disease: Are combinations more effective?","volume":"124","author":"Sharman","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biopha.2018.11.043","article-title":"Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by A\u03b2 peptides in animal model of Alzheimer\u2019s disease","volume":"110","author":"Rahman","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"10388","DOI":"10.18632\/oncotarget.23737","article-title":"Astaxanthin is neuroprotective in an aged mouse model of Parkinson\u2019s disease","volume":"9","author":"Grimmig","year":"2017","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.joim.2018.07.001","article-title":"Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers","volume":"16","author":"Jamwal","year":"2018","journal-title":"J. Integr. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuint.2015.07.003","article-title":"Bioavailability of dietary polyphenols: Factors contributing to their clinical application in CNS diseases","volume":"89","author":"Pandareesh","year":"2015","journal-title":"Neurochem. Int."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.phrs.2017.08.004","article-title":"Curcumin in Alzheimer\u2019s disease: Can we think to new strategies and perspectives for this molecule?","volume":"124","author":"Serafini","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/8\/1519\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:46:16Z","timestamp":1760186776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/8\/1519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,17]]},"references-count":131,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["molecules24081519"],"URL":"https:\/\/doi.org\/10.3390\/molecules24081519","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,17]]}}}